{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:46:00Z","timestamp":1787024760359,"version":"build-2736575974"},"reference-count":260,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Viral vectors have proven useful in a broad spectrum of gene therapy applications due to their possibility to accommodate foreign genetic material for both local and systemic delivery. The wide range of viral vectors has enabled gene therapy applications for both acute and chronic diseases. Cancer gene therapy has been addressed by delivery of viral vectors expressing anti-tumor, toxic, and suicide genes for destruction of tumors. Delivery if immunostimulatory genes such as cytokines and chemokines has also been applied for cancer therapy. Moreover, oncolytic viruses specifically replicating in and killing tumor cells have been used as such for tumor eradication or in combination with tumor killing or immunostimulatory genes. In a broad meaning, vaccines against infectious diseases and various cancers can be considered as gene therapy, which has been highly successful not the least for development of effective COVID-19 vaccines. Viral vector-based gene therapy has also demonstrated encouraging and promising results for chronic diseases such as severe combined immunodeficiency (SCID), muscular dystrophy, and hemophilia. Preclinical gene therapy studies in animal models have demonstrated proof-of-concept for a wide range of disease indications. Clinical evaluation of drugs and vaccines in humans has showed high safety levels, good tolerance, and therapeutic efficacy. Several gene therapy drugs such as the adenovirus-based drug Gendicine\u00ae for non-small-cell lung cancer, the reovirus-based drug Reolysin\u00ae for ovarian cancer, lentivirus-based treatment of SCID-X1 disease, and the rhabdovirus-based vaccine Ervebo against Ebola virus disease, and adenovirus-based vaccines against COVID-19 have been developed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1566523222666220921112753","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:29:43Z","timestamp":1663892983000},"page":"111-134","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Gene Therapy Cargoes Based on Viral Vector Delivery"],"prefix":"10.2174","volume":"23","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/B978-0-12-416603-5.00002-X","author":"Lundstrom K.","year":"2015","unstructured":"Lundstrom K.;  New era in gene therapy Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies 2015,15-37","journal-title":"New era in gene therapy Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00439-013-1288-1","volume":"132","author":"Martinez T.","year":"2013","unstructured":"Martinez T.; Wright N.; L&#xF3;pez-Fraga M.; Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 2013,132,481-493","journal-title":"Hum Genet"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-pharmtox-010715-103633","volume":"56","author":"Bobbin M.L.","year":"2016","unstructured":"Bobbin M.L.; Rossi J.J.; RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 2016,56,103-122","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/B978-0-12-416603-5.00015-8","author":"Ramirez-Montagut T.","year":"2015","unstructured":"Ramirez-Montagut T.;  Cancer vaccines Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies 2015,365-388","journal-title":"Cancer vaccines Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"Sermer D.","year":"2019","unstructured":"Sermer D.; Brentjens R.; CAR-T cell therapy: full speed ahead. Hematol Oncol 2019,37,95-100","journal-title":"Hematol Oncol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","volume":"25","author":"Lino C.A.","year":"2018","unstructured":"Lino C.A.; Harper J.C.; Carney J.P.; Delivering CRISPR: a review of the challenges and approaches. Drug Deliv 2018,25,1234-1257","journal-title":"Drug Deliv"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","volume":"118","author":"Hacein-Bey-Abina S.","year":"2008","unstructured":"Hacein-Bey-Abina S.; Garrigue A.; Wang G.P.; (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008,118,3132-3142","journal-title":"J Clin Invest"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","volume":"80","author":"Raper S.E.","year":"2003","unstructured":"Raper S.E.; Chirmule N.; Lee F.S.; Fatal systemic inflammatory response syndrome in an ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003,80,148-158","journal-title":"Mol Genet Metab"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"Fukuhara H.","year":"2016","unstructured":"Fukuhara H.; Ino Y.; Todo T.; Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci 2016,107,1373-1379","journal-title":"Cancer Sci"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","volume":"10","author":"Tatsis N.","year":"2004","unstructured":"Tatsis N.; Ertl H.C.J.; Adenoviruses as vaccine vectors. Mol Ther 2004,10,616-629","journal-title":"Mol Ther"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/156652312800099599","volume":"12","author":"Wang F.","year":"2012","unstructured":"Wang F.; Wang Z.; Tian H.; Biodistribution and safety assessment of bladder cancer specific oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr Gene Ther 2012,12,67-76","journal-title":"Curr Gene Ther"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.3390\/ijms21103643","volume":"21","author":"Ricobaraza A.","year":"2020","unstructured":"Ricobaraza A.; Gonzalez-Aparicio M.; Mora-Jimenez L.; High-Capacity Adenovirus Vectors: Expanding the Scope of Gene Therapy. Int J Mol Sci 2020,21,3643","journal-title":"Int J Mol Sci"},{"key":"ref=13","first-page":"e52894","volume":"107","author":"Ehrke-Schulz E.","year":"2016","unstructured":"Ehrke-Schulz E.; Zhang W.; Schiwon M.; Cloning and Large-Scale Production of High-Capacity Adenoviral Vectors Based on the Human Adenovirus Type 5. J Vis Exp 2016,107,e52894","journal-title":"J Vis Exp"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1159\/000475909","volume":"41","author":"Wei Q.","year":"2017","unstructured":"Wei Q.; Fan J.; Liao J.; Engineering the rapid adenovirus production and amplification (RAPA) cell line to expedite the generation of recombinant adenoviruses. Cell Physiol Biochem 2017,41,2383-2398","journal-title":"Cell Physiol Biochem"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","volume":"29","author":"Zhang W.W.","year":"2018","unstructured":"Zhang W.W.; Li L.; Li D.; The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther 2018,29,160-179","journal-title":"Hum Gene Ther"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.37349\/ei.2021.00020","volume":"1","author":"Lundstrom K.","year":"2021","unstructured":"Lundstrom K.; Viral vector-based vaccines against SARS-CoV-2. Explor Immunol 2021,1,295-308","journal-title":"Explor Immunol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","volume":"1","author":"Samulski R.","year":"2014","unstructured":"Samulski R.; Muzycka N.; AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 2014,1,427-451","journal-title":"Annu Rev Virol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","volume":"79","author":"Grieger C.","year":"2005","unstructured":"Grieger C.; Samulski R.J.; Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005,79,9933-9944","journal-title":"J Virol"},{"key":"ref=19","first-page":"611","volume":"90","author":"McClements M.E.","year":"2017","unstructured":"McClements M.E.; MacLaren R.R.; Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes. Yale J Biol Med 2017,90,611-623","journal-title":"Yale J Biol Med"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2741\/2872","volume":"13","author":"Park K.","year":"2008","unstructured":"Park K.; Kim W.J.; Cho Y.H.; Cancer gene therapy using adeno-associated virus vectors. Front Biosci 2008,13,2653-2659","journal-title":"Front Biosci"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"Nienhuis A.W.","year":"2017","unstructured":"Nienhuis A.W.; Nathwani A.C.; Davidoff A.M.; Gene therapy for hemophilia. Mol Ther 2017,25,1163-1167","journal-title":"Mol Ther"},{"key":"ref=22","first-page":"272","volume":"28","author":"Moorehead T.","year":"2020","unstructured":"Moorehead T.; Yong F.; Neelakantan S.; Safety and tolerability of PF-06939926 in ambulatory boys with Duchenne muscular dystrophy: a phase 1b multicenter, open label, dose ascending study. Mol Ther 2020,28,272","journal-title":"Mol Ther"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"Mingozzi F.","year":"2013","unstructured":"Mingozzi F.; High K.A.; Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013,122,23-36","journal-title":"Blood"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","volume":"1","author":"Meliani A.","year":"2017","unstructured":"Meliani A.; Boisgerault F.; Fitzpatrick Z.; Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv 2017,1,2019-2031","journal-title":"Blood Adv"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2174\/156652305774329285","volume":"5","author":"Epstein A.L.","year":"2005","unstructured":"Epstein A.L.; Marconi P.; Argnani R.; HSV-1 derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr Gene Ther 2005,5,445-458","journal-title":"Curr Gene Ther"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/13550280009006380","volume":"6","author":"Holmes K.D.","year":"2000","unstructured":"Holmes K.D.; Cassam A.K.; Chan B.; A multi-mutant herpes simplex virus vector has minimal cytotoxic effects on the distribution of filamentous actin, alpha-actinin and a glutamate receptor in differentiated PC-12 cells. J Neurovirol 2000,6,33-45","journal-title":"J Neurovirol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1743-422X-10-241","volume":"10","author":"Li J.M.","year":"2013","unstructured":"Li J.M.; Kao K.C.; Li L.F.; Micro-RNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small lung cancer cells. Virol J 2013,10,241","journal-title":"Virol J"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","volume":"18","author":"Bommareddy P.K.","year":"2017","unstructured":"Bommareddy P.K.; Patel A.; Hossain S.; Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. J Clin Dermatol 2017,18,1-15","journal-title":"J Clin Dermatol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-42934-2_2","volume":"209","author":"Schambach A.","year":"2016","unstructured":"Schambach A.; Morgan M.; Retroviral vectors for cancer gene therapy. Curr Strat Cancer Gene Ther 2016,209,17-35","journal-title":"Curr Strat Cancer Gene Ther"},{"key":"ref=30","first-page":"493","volume":"52","author":"Hu W.S.","year":"2000","unstructured":"Hu W.S.; Pathak V.K.; Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000,52,493-511","journal-title":"Pharmacol Rev"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41417-018-0020-7","volume":"25","author":"Inoko K.","year":"2018","unstructured":"Inoko K.; Hiraoka K.; Inagaki A.; Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer. Cancer Gene Ther 2018,25,184-195","journal-title":"Cancer Gene Ther"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","volume":"106","author":"Heinzerling L.","year":"2005","unstructured":"Heinzerling L.; Kunzi V.; Oberholzer P.A.; Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon resistant tumor cells. Blood 2005,106,2287-2294","journal-title":"Blood"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","volume":"371","author":"Hacein-Bey-Abina S.","year":"2014","unstructured":"Hacein-Bey-Abina S.; Pai S.Y.; Gaspar H.B.; A modified &#x3B3;-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014,371,1407-1417","journal-title":"N Engl J Med"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","volume":"2","author":"Vigna E.","year":"2000","unstructured":"Vigna E.; Naldini L.; Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000,2,308-316","journal-title":"J Gene Med"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","volume":"7","author":"Kay M.A.","year":"2001","unstructured":"Kay M.A.; Glorioso J.C.; Naldini L.; Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001,7,33-40","journal-title":"Nat Med"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156652308786848021","volume":"8","author":"Ciuffi A.","year":"2008","unstructured":"Ciuffi A.; Mechanisms governing lentivirus integration site selection. Curr Gene Ther 2008,8,419-429","journal-title":"Curr Gene Ther"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/hum.2009.134","volume":"21","author":"Silvers R.M.","year":"2010","unstructured":"Silvers R.M.; Smith J.A.; Schowalter M.; Modification of integration site preferences of an HIV-1-based vector by expression of a novel synthetic protein. Hum Gene Ther 2010,21,337-349","journal-title":"Hum Gene Ther"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1089\/10430340050129486","volume":"11","author":"Nakajima T.","year":"2000","unstructured":"Nakajima T.; Nakamaru K.; Ido E.; (2000) Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 2000,11,1863-1874","journal-title":"Hum Gene Ther"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/v4112684","volume":"4","author":"Hartmann K.","year":"2012","unstructured":"Hartmann K.; Clinical aspects of feline retroviruses: a review. Viruses 2012,4,2684-2710","journal-title":"Viruses"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.gt.3300768","volume":"5","author":"Olsen J.C.","year":"1998","unstructured":"Olsen J.C.; Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998,5,1481-1487","journal-title":"Gene Ther"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","volume":"376","author":"Ribel J-A.","year":"2017","unstructured":"Ribel J-A.; Hacein-Bey-Abina S.; Paven E.; Gene therapy in a patient with sickle cell disease. N Engl J Med 2017,376,848-855","journal-title":"N Engl J Med"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","volume":"326","author":"Cartier N.","year":"2009","unstructured":"Cartier N.; Hacein-Bey-Abina S.; Bartholomae C.C.; Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009,326,818-823","journal-title":"Science"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jaci.2018.08.024","volume":"143","author":"Kohn D.B.","year":"2019","unstructured":"Kohn D.B.; Hershfield M.S.; Puck J.M.; Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency. J Allergy Clin Immunol 2019,143,852-863","journal-title":"J Allergy Clin Immunol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","volume":"58","author":"Strauss J.H.","year":"1994","unstructured":"Strauss J.H.; Strauss E.G.; The alphaviruses; gene expression, replication and evolution. Microbiol Rev 1994,58,491-562","journal-title":"Microbiol Rev"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/ijms21145130","volume":"2020","author":"Lundstrom K.","year":"2020","unstructured":"Lundstrom K.; Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci 2020,2020,5130","journal-title":"Int J Mol Sci"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","volume":"9","author":"Liljestr&#xF6;m P.","year":"1991","unstructured":"Liljestr&#xF6;m P.; Garoff H.; A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 1991,9,1356-1361","journal-title":"Biotechnology (N Y)"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","volume":"243","author":"Xiong C.","year":"1989","unstructured":"Xiong C.; Levis R.; Shen P.; Sindbis virus: An efficient, broad host range vector for gene expression in animal cells. Science 1989,243,1188-1191","journal-title":"Science"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","volume":"171","author":"Davis N.L.","year":"1989","unstructured":"Davis N.L.; Willis L.V.; Smith J.F.; In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant. Virology 1989,171,189-204","journal-title":"Virology"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/08830180490265529","volume":"23","author":"Li M.","year":"2004","unstructured":"Li M.; Stollar V.; Alphaviruses and apoptosis. Int Rev Immunol 2004,23,7-24","journal-title":"Int Rev Immunol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"e8603","DOI":"10.1371\/journal.pone.0008603","volume":"5","author":"Heikkil&#xE4; J.E.","year":"2010","unstructured":"Heikkil&#xE4; J.E.; V&#xE4;h&#xE4;-Koskela M.J.; Ruotsalainen J.J.; Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010,5,e8603","journal-title":"PLoS One"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","volume":"40","author":"Zhang J.","year":"2021","unstructured":"Zhang J.; Liu Y.; Tan J.; Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC. Oncogene 2021,40,4783-4795","journal-title":"Oncogene"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1517\/14712598.6.2.135","volume":"6","author":"Pijlman G.P.","year":"2006","unstructured":"Pijlman G.P.; Suhrbier A.; Khromykh A.A.; Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006,6,134-145","journal-title":"Expert Opin Biol Ther"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"11605","DOI":"10.1128\/JVI.78.21.11605-11614.2004","volume":"78","author":"Scholle I.","year":"2004","unstructured":"Scholle I.; Girard Y.A.; Zhao Q.; Trans-packaged West Nile virus-like particles: infectious properties in vitro and in infected mosquito vectors. J Virol 2004,78,11605-11614","journal-title":"J Virol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2180-1-18","volume":"1","author":"Pang X.","year":"2001","unstructured":"Pang X.; Zhang M.; Dayton A.I.; Development of dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol 2001,1,18","journal-title":"BMC Microbiol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.77.16.8924-8933.2003","volume":"77","author":"Gherke R.","year":"2003","unstructured":"Gherke R.; Ecker M.; Aberle S.W.; Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line. J Virol 2003,77,8924-8933","journal-title":"J Virol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.virol.2004.10.034","volume":"331","author":"Jones C.T.","year":"2005","unstructured":"Jones C.T.; Patkar C.G.; Kuhn R.J.; Construction and applications of yellow fever virus replicons. Virology 2005,331,247-259","journal-title":"Virology"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1128\/JVI.72.7.5967-5977.1998","volume":"72","author":"Khromykh A.A.","year":"1998","unstructured":"Khromykh A.A.; Varnavski A.N.; Westaway E.G.; Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans. J Virol 1998,72,5967-5977","journal-title":"J Virol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/vaccines4020009","volume":"4","author":"Apostolopoulos V.","year":"2016","unstructured":"Apostolopoulos V.; Vaccine delivery methods into the future. Vaccine 2016,4,9","journal-title":"Vaccine"},{"key":"ref=59","first-page":"1","volume":"15","author":"Lundstrom K.","unstructured":"Lundstrom K.; Self-replicating vehicles based on negative strand RNA viruses. Cancer Gene Ther ,15,1-14","journal-title":"Cancer Gene Ther"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","volume":"73","author":"Singh M.","year":"1999","unstructured":"Singh M.; Cattaneo R.; Billeter M.A.; A recombinant measles virus expressing hepatitis B surface antigen induces humoral responses in genetically modified mice. J Virol 1999,73,4823-4828","journal-title":"J Virol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"eaaw3163","DOI":"10.1126\/scitranslmed.aaw3163","volume":"11","author":"Mateo M.","year":"2019","unstructured":"Mateo M.; Reynard S.; Carnec X.; Vaccines inducing immunity to Lassa fever glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med 2019,11,eaaw3163","journal-title":"Sci Transl Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/hum.2012.205","volume":"24","author":"Grossardt C.","year":"2013","unstructured":"Grossardt C.; Engeland C.E.; Bossow S.; Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013,24,644-654","journal-title":"Hum Gene Ther"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pros.20857","volume":"69","author":"Msaouel P.","year":"2009","unstructured":"Msaouel P.; Iankov I.D.; Allen C.; Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 2009,69,82-91","journal-title":"Prostate"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1089\/hum.2012.136","volume":"24","author":"Lange S.","year":"2013","unstructured":"Lange S.; Lampe J.; Bossow S.; A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Hum Gene Ther 2013,24,554-564","journal-title":"Hum Gene Ther"},{"key":"ref=65","first-page":"165","volume":"292","author":"Finke S.","year":"2005","unstructured":"Finke S.; Conzelmann K.K.; Recombinant rhabdoviruses: vectors for vaccine development and gene therapy. Curr Top Microbiol Immunol 2005,292,165-200","journal-title":"Curr Top Microbiol Immunol"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","volume":"47","author":"Ito N.","year":"2003","unstructured":"Ito N.; Takayama-Ito M.; Yamada K.; Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol Immunol 2003,47,613-617","journal-title":"Microbiol Immunol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11262-016-1313-2","volume":"52","author":"Luo J.","year":"2016","unstructured":"Luo J.; Zhao J.; Tian Q.; A recombinant rabies virus carrying GFP between N and P affects viral transcription in vitro. Virus Genes 2016,52,379-387","journal-title":"Virus Genes"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virusres.2012.11.007","volume":"171","author":"An H.","year":"2013","unstructured":"An H.; Kim G.N.; Kang C.Y.; Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression. Virus Res 2013,171,168-177","journal-title":"Virus Res"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","volume":"22","author":"Pol J.G.","year":"2014","unstructured":"Pol J.G.; Zhang L.; Bridle B.W.; Maraba virus as a potent oncolytic vaccine vector. Mol Ther 2014,22,420-429","journal-title":"Mol Ther"},{"key":"ref=70","unstructured":"Phase 2b\/3 Trial of VSV-\u0394G SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine. (BRILIFE002)  (Accessed on January 27, 2022)."},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","volume":"181","author":"Ollmann Saphire E.","year":"2020","unstructured":"Ollmann Saphire E.; A vaccine against Ebola virus. Cell 2020,181,6","journal-title":"Cell"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","volume":"184","author":"Ganar K.","year":"2014","unstructured":"Ganar K.; Das M.; Sinha S.; Newcastle disease virus: current status and our understanding. Virus Res 2014,184,71-81","journal-title":"Virus Res"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0022-4804(92)90310-V","volume":"52","author":"Reichard K.","year":"1992","unstructured":"Reichard K.; Lorence R.M.; Cascino C.J.; Newcastle disease virus selectively kills human tumor cells. J Surg Res 1992,52,448-453","journal-title":"J Surg Res"},{"key":"ref=74","first-page":"945","volume":"18","author":"Schirrmacher V.","year":"2001","unstructured":"Schirrmacher V.; Griesbach A.; Ahlert T.; Antitumor effects of Newcastle disease virus in vivo: local versus systemic effects. Int J Oncol 2001,18,945-952","journal-title":"Int J Oncol"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1128\/JVI.00136-16","volume":"90","author":"Cheng X.","year":"2016","unstructured":"Cheng X.; Wang W.; Xu Q.; Genetic modification of oncolytic Newcastle disease virus for cancer therapy. J Virol 2016,90,5343-5352","journal-title":"J Virol"},{"key":"ref=76","first-page":"161","volume":"6","author":"Kwak H.","year":"2003","unstructured":"Kwak H.; Honig H.; Kaufman H.L.; (2003) Poxviruses as vectors for cancer immunotherapy. Curr Opin Drug Discov Devel 2003,6,161-168","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-3-030-85395-2_9","author":"Lundstrom K.","year":"2022","unstructured":"Lundstrom K.;  Application of Viruses for Gene Therapy and Vaccine Development The Biological Role of a Virus 2022,285-341","journal-title":"Application of Viruses for Gene Therapy and Vaccine Development The Biological Role of a Virus"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.cgt.7700549","volume":"9","author":"Zeh H.J.","year":"2002","unstructured":"Zeh H.J.; Bartlett D.L.; Development of a replication-selective oncolytic proxvirus for the treatment of human cancers. Cancer Gene Ther 2002,9,1001-1012","journal-title":"Cancer Gene Ther"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0147-9571(03)00019-5","volume":"26","author":"Pastoret P-P.","year":"2003","unstructured":"Pastoret P-P.; Vanderplasschen A.; Poxviruses as vaccine vectors. Comp Immunol Microbiol Infect Dis 2003,26,343-355","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.cgt.7700538","volume":"9","author":"Mastrangelo M.J.","year":"2002","unstructured":"Mastrangelo M.J.; Lattime E.C.; Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther 2002,9,1013-1021","journal-title":"Cancer Gene Ther"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.7.4.543","volume":"7","author":"Madan R.A.","year":"2007","unstructured":"Madan R.A.; Arlen P.M.; Gullye J.L.; PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. Expert Opin Biol Ther 2007,7,543-554","journal-title":"Expert Opin Biol Ther"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2147\/OV.S56322","volume":"3","author":"Bradley S.","year":"2014","unstructured":"Bradley S.; Jakes A.D.; Harrington K.; Applications of coxsackievirus A21 in oncology. Oncolytic Virother 2014,3,47-55","journal-title":"Oncolytic Virother"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/hv.7.4.14422","volume":"7","author":"Kim D-S.","year":"2011","unstructured":"Kim D-S.; Nam J-H.; Application of attenuated coxsackievirus B3 as viral vector system for vaccines and gene therapy. Hum Vaccin 2011,7,410-416","journal-title":"Hum Vaccin"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/135502802317247776","volume":"8","author":"Jia Q.","year":"2002","unstructured":"Jia Q.; Liang F.; Ohka S.; Expression of brain-derived neurotrophic factor in the central nervous system of mice using a poliovirus-based vector. J Neurovirol 2002,8,14-23","journal-title":"J Neurovirol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1158\/1078-0432.CCR-0690-3","volume":"10","author":"Shafren D.R.","year":"2014","unstructured":"Shafren D.R.; Au G.G.; Nguyen T.; Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 2014,10,53-60","journal-title":"Clin Cancer Res"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10637-010-9614-0","volume":"30","author":"Skelding K.A.","year":"2012","unstructured":"Skelding K.A.; Barry R.D.; Shafren D.R.; Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs 2012,30,568-581","journal-title":"Invest New Drugs"},{"key":"ref=87","first-page":"69","volume":"3","author":"Clements D.","year":"2014","unstructured":"Clements D.; Helson E.; Gujar S.A.; Reovirus in cancer therapy: an evidence-based review. Oncol Virother 2014,3,69-82","journal-title":"Oncol Virother"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1158\/1535-7163.MCT-10-0590","volume":"9","author":"Gujar S.A.","year":"2010","unstructured":"Gujar S.A.; Marcato P.; Pan D.; Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Mol Cancer Ther 2010,9,2924-2933","journal-title":"Mol Cancer Ther"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2174\/1389201043376670","volume":"5","author":"Kimchi-Sarfaty C.","year":"2004","unstructured":"Kimchi-Sarfaty C.; Gottesman M.M.; SV40 pseudovirions as highly efficient vectors for gene 1589 transfer and their potential application in cancer therapy. Curr Pharm Biotechnol 2004,5,451-458","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.omtm.2017.06.007","volume":"6","author":"Toscano M.G.","year":"2017","unstructured":"Toscano M.G.; van der Velden J.; van der Werf S.; Generation of a Vero-based packaging cell line to produce SV40 gene delivery vectors for use in clinical gene therapy studies. Mol Ther Methods Clin Dev 2017,6,124-134","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.cgt.7700987","volume":"14","author":"Cordelier P.","year":"2007","unstructured":"Cordelier P.; Bienvenu C.; Lulka H.; Replication-deficient rSV40 mediate pancreatic gene transfer and long-term inhibition of tumor growth. Cancer Gene Ther 2007,14,19-29","journal-title":"Cancer Gene Ther"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2005-10-4114","volume":"107","author":"Liu Y.","year":"2006","unstructured":"Liu Y.; Deisseroth A.; Tumor vascular targeting therapy with viral vectors. Blood 2006,107,3027-3033","journal-title":"Blood"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"605380","DOI":"10.3389\/fonc.2020.605380","volume":"10","author":"Monta&#xF1;o-Samaniego M.","year":"2020","unstructured":"Monta&#xF1;o-Samaniego M.; Bravo-Estupi&#xF1;an D.M.; M&#xE9;ndez-Guerrero O.; Strategies for Targeting Gene Therapy in Cancer Cells with Tumor-Specific Promoters. Front Oncol 2020,10,605380","journal-title":"Front Oncol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","volume":"7","author":"Eissa I.R.","year":"2017","unstructured":"Eissa I.R.; Naoe Y.; Bustos-Villalobos I.; Genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials. Front Oncol 2017,7,149","journal-title":"Front Oncol"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/cancers10060205","volume":"10","author":"Mostafa A.A.","year":"2018","unstructured":"Mostafa A.A.; Meyers D.E.; Thirukkumaran C.M.; Oncolytic Reovirus and immune checkpoint inhibitor as a novel immunotherapeutic strategy for breast cancer. Cancers 2018,10,205","journal-title":"Cancers"},{"key":"ref=96","first-page":"E4504","volume":"111","author":"Lin Y.","year":"2014","unstructured":"Lin Y.; Zhang H.; Liang J.; Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers. Proc Natl Acad Sci USA 2014,111,E4504-E4512","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.4161\/cc.8.20.9832","volume":"8","author":"Hu J.","year":"2009","unstructured":"Hu J.; Cai X.F.; Yan G.; Alphavirus M1 induces apoptosis of malignant glioma cells via downregulation and nucleolat translocation of p21WAF1\/CIP1 protein. Cell Cycle 2009,8,3328-3339","journal-title":"Cell Cycle"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2990.2010.01110.x","volume":"36","author":"Roche F.P.","year":"2010","unstructured":"Roche F.P.; Sheahan B.J.; O\u2019Mara S.M.; Semliki Forest virus-mediated gene therapy of the RG2 rat glioma. Neuropathol Appl Neurobiol 2010,36,648-660","journal-title":"Neuropathol Appl Neurobiol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/hum.2014.100","volume":"26","author":"Huang T.T.","year":"2015","unstructured":"Huang T.T.; Parab S.; Burnett R.; Intravenous administration of retroviral replicating vector, Toca 511, demonstrates efficacy in orthotopic immune-competent mouse glioma model. Hum Gene Ther 2015,26,82-93","journal-title":"Hum Gene Ther"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2008.169","volume":"16","author":"Hoang-Le D.","year":"2009","unstructured":"Hoang-Le D.; Smeenk L.; Anraku I.; A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther 2009,16,190-199","journal-title":"Gene Ther"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/10548","volume":"5","author":"Ying H.","year":"1999","unstructured":"Ying H.; Zaks T.Z.; Wang R-F.; Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999,5,823-827","journal-title":"Nat Med"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7785\/tcrt.2012.500414","volume":"14","author":"Niu Z.","year":"2015","unstructured":"Niu Z.; Bai F.; Sun T.; Recombinant Newcastle disease virus expressing IL15 demonstrates promising antitumor efficiency in melanoma model. Technol Cancer Res Treat 2015,14,607-615","journal-title":"Technol Cancer Res Treat"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-008-9899-2","volume":"113","author":"Skelding K.A.","year":"2009","unstructured":"Skelding K.A.; Barry R.D.; Shafren D.R.; Systemic targeting of metastatic human breast xenografts by Coxsackievirus A21. Breast Cancer Res Treat 2009,113,21-30","journal-title":"Breast Cancer Res Treat"},{"key":"ref=104","first-page":"3599","volume":"37","author":"Nagasato M.","year":"2017","unstructured":"Nagasato M.; Rin Y.; Yamamoto Y.; A tumor-targeting adenovirus with high gene transduction efficiency for primary pancreatic cancer and ascites cells. Anticancer Res 2017,37,3599-3605","journal-title":"Anticancer Res"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/cam4.1185","volume":"6","author":"Yamamoto Y.","year":"2017","unstructured":"Yamamoto Y.; Nagasato M.; Rin Y.; Strong antitumor efficacy of a pancreatic tumor targeting oncolytic adenovirus for neuroendocrine tumors. Cancer Med 2017,6,2385-2397","journal-title":"Cancer Med"},{"key":"ref=106","first-page":"1218","volume":"9","author":"Etoh T.","year":"2003","unstructured":"Etoh T.; Himeno Y.; Matsumoto T.; Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 2003,9,1218-1223","journal-title":"Clin Cancer Res"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14760584.5.1.9","volume":"5","author":"Petrulio C.A.","year":"2006","unstructured":"Petrulio C.A.; Kaufman H.L.; Development of the panvac-vf vaccine for pancreatic cancer. Expert Rev Vaccines 2006,5,9-19","journal-title":"Expert Rev Vaccines"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.surg.2015.03.044","volume":"158","author":"Ady J.W.","year":"2015","unstructured":"Ady J.W.; Johnsen C.; Mojica K.; Oncolytic gene therapy with recombinant vaccinia virus strain GLV-2b372 efficiently kills hepatocellular carcinoma. Surgery 2015,158,331-338","journal-title":"Surgery"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/gt.2016.5","volume":"23","author":"Mansfield D.C.","year":"2016","unstructured":"Mansfield D.C.; Kyula J.N.; Rosenfelder N.; Oncolytic vaccinia virus as a vector for 1688 therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther 2016,23,357-368","journal-title":"Gene Ther"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","volume":"18","author":"Hirooka Y.","year":"2018","unstructured":"Hirooka Y.; Kasuya H.; Ishikawa T.; A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer 2018,18,596","journal-title":"BMC Cancer"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"341ra75","DOI":"10.1126\/scitranslmed.aad9784","volume":"8","author":"Cloughesy T.F.","year":"2016","unstructured":"Cloughesy T.F.; Landolfi J.; Hogan D.J.; Phase I trial of vocimagine amiroretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med 2016,8,341ra75","journal-title":"Sci Transl Med"},{"key":"ref=112","unstructured":"Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer. Tocagen. Published September 12, 2019. \n Accessed March 2, 2022."},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","volume":"70","author":"Galanis E.","year":"2010","unstructured":"Galanis E.; Hartmann L.C.; Cliby W.A.; Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010,70,875-882","journal-title":"Cancer Res"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/mt.2016.101","volume":"24","author":"Downs-Canner S.","year":"2016","unstructured":"Downs-Canner S.; Guo Z.S.; Ravindranathan R.; Phase I study of intravenous oncolytic poxvirus (vvDD) in patients with advanced solid cancers. Mol Ther 2016,24,1492-1501","journal-title":"Mol Ther"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2002.08.042","volume":"20","author":"Pecora A.L.","year":"2002","unstructured":"Pecora A.L.; Rizvi N.; Cohen G.I.; Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002,20,2251-2266","journal-title":"J Clin Oncol"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1158\/1078-0432.CCR-11-0649","volume":"17","author":"Mohebtash M.","year":"2011","unstructured":"Mohebtash M.; Tsang K.Y.; Madan R.A.; A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011,17,7164-7173","journal-title":"Clin Cancer Res"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"12100","DOI":"10.1073\/pnas.94.22.12100","volume":"94","author":"Akhter S.A.","year":"1997","unstructured":"Akhter S.A.; Skaer C.A.; Kypson A.P.; Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. Proc Natl Acad Sci USA 1997,94,12100-12105","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","volume":"97","author":"Miyamoto M.I.","year":"2000","unstructured":"Miyamoto M.I.; del Monte F.; Schmidt U.; Adenoviral gene transfer of SERCa2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci USA 2000,97,793-798","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"H1204","DOI":"10.1152\/ajpheart.00892.2006","volume":"292","author":"Sakata S.","year":"2007","unstructured":"Sakata S.; Lebeche D.; Sakata Y.; Transcoronary transfer of SERCa2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol 2007,292,H1204-H1207","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/hrt.2009.180414","volume":"97","author":"Zachary I.","year":"2011","unstructured":"Zachary I.; Morgan R.D.; Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects. Heart 2011,97,181-189","journal-title":"Heart"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0008-6363(99)00203-5","volume":"44","author":"Lazarous D.F.","year":"1999","unstructured":"Lazarous D.F.; Shou M.; Stiber J.A.; Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999,44,294-302","journal-title":"Cardiovasc Res"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s11033-009-9665-5","volume":"37","author":"Yang Z-J.","year":"2010","unstructured":"Yang Z-J.; Chen B.; Shen Z.; Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor transfer: comparison of low-, medium- and high-dose groups. Mol Biol Rep 2010,37,2075-2081","journal-title":"Mol Biol Rep"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1161\/CIRCULATIONAHA.111.053272","volume":"125","author":"Igarashi T.","year":"2012","unstructured":"Igarashi T.; Finet J.E.; Takeuchi A.; Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 2012,125,216-225","journal-title":"Circulation"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.109.911156","volume":"121","author":"Amit G.","year":"2010","unstructured":"Amit G.; Kikuchi K.; Greener I.D.; Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation 2010,121,2263-2270","journal-title":"Circulation"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCHEARTFAILURE.112.971325","volume":"6","author":"Fish K.M.","year":"2013","unstructured":"Fish K.M.; Ladage D.; Kawase Y.; AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Clin Heart Fail 2013,6,310-317","journal-title":"Clin Heart Fail"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","volume":"126","author":"Wang S.","year":"2020","unstructured":"Wang S.; Li Y.; Xu Y.; AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine Knockout Model of Barth Syndrome. Circ Res 2020,126,1024-1039","journal-title":"Circ Res"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/mt.2010.77","volume":"18","author":"Hadri L.","year":"2010","unstructured":"Hadri L.; Bobe R.; Kawase Y.; SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther 2010,18,1284-1292","journal-title":"Mol Ther"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","volume":"34","author":"Raake P.W.J.","year":"2013","unstructured":"Raake P.W.J.; Schlegel P.; Ksienzyk J.; AAV6.&#x3B2;ARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 2013,34,1437-1447","journal-title":"Eur Heart J"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nature11044","volume":"485","author":"Qian L.","year":"2012","unstructured":"Qian L.; Huang Y.; Spencer C.I.; In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012,485,593-598","journal-title":"Nature"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/mt.2008.61","volume":"16","author":"Niwano K.","year":"2008","unstructured":"Niwano K.; Arai M.; Koitabashi N.; Lentiviral vector\u2013mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther 2008,16,1026-1032","journal-title":"Mol Ther"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/cvr\/cvv205","volume":"108","author":"Rincon M.Y.","year":"2015","unstructured":"Rincon M.Y.; VandenDriessche T.; Chuah M.K.; Gene therapy for cardiovascular disease: advances in vector development, targeting, and delivery for clinical translation. Cardiovasc Res 2015,108,4-20","journal-title":"Cardiovasc Res"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","volume":"13","author":"Stewart D.J.","year":"2006","unstructured":"Stewart D.J.; Hilton J.D.; Arnold J.M.O.; Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment. Gene Ther 2006,13,1503-1511","journal-title":"Gene Ther"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-021-00295-1","author":"Leikas A.J.","year":"2021","unstructured":"Leikas A.J.; Hassinen I.; Hedman A.; Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D\u0394N\u0394C gene therapy eight-year follow-up of phase I KAT301 study. Gene Ther 2021","journal-title":"Gene Ther"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hc1102.105595","volume":"105","author":"Grines C.L.","year":"2002","unstructured":"Grines C.L.; Watkins M.W.; Helmer G.; Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002,105,1291-1297","journal-title":"Circulation"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","volume":"42","author":"Grines C.L.","year":"2003","unstructured":"Grines C.L.; Watkins M.W.; Mahmarian J.J.; A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003,42,1339-1347","journal-title":"J Am Coll Cardiol"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","volume":"50","author":"Henry T.D.","year":"2007","unstructured":"Henry T.D.; Grines C.L.; Watkins M.W.; Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol 2007,50,1038-1046","journal-title":"J Am Coll Cardiol"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cardfail.2009.01.013","volume":"15","author":"Jaski B.E.","year":"2009","unstructured":"Jaski B.E.; Jessup M.L.; Mancini D.M.; Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1\/2 clinical trial. J Card Fail Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators2009,15,171-181","journal-title":"J Card Fail"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"Jessup M.","year":"2011","unstructured":"Jessup M.; Greenberg B.; Mancini D.; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators2011,124,304-313","journal-title":"Circulation"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","volume":"114","author":"Zsebo K.","year":"2014","unstructured":"Zsebo K.; Yaroshinsky A.; Rudy J.J.; Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014,114,101-108","journal-title":"Circ Res"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/gt.2008.64","volume":"15","author":"Alexander I.E.","year":"2008","unstructured":"Alexander I.E.; Cunningham S.C.; Logan G.J.; Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 2008,15,831-839","journal-title":"Gene Ther"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.gt.3300775","volume":"5","author":"Watson G.L.","year":"1998","unstructured":"Watson G.L.; Sayles J.N.; Chen C.; Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther 1998,5,1642-1649","journal-title":"Gene Ther"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ymthe.2006.03.009","volume":"14","author":"Moscioni D.","year":"2006","unstructured":"Moscioni D.; Morizono H.; McCarter R.J.; Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. Mol Ther 2006,14,25-33","journal-title":"Mol Ther"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jgm.554","volume":"6","author":"Lebherz C.","year":"2004","unstructured":"Lebherz C.; Gao G.; Louboutin J.P.; Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 2004,6,663-672","journal-title":"J Gene Med"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"e8791","DOI":"10.15252\/emmm.201708791","volume":"10","author":"Jimenez V.","year":"2018","unstructured":"Jimenez V.; Jambrina C.; Casana E.; FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Mol Med 2018,10,e8791","journal-title":"EMBO Mol Med"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s00268-007-9168-2","volume":"31","author":"Xu J.","year":"2007","unstructured":"Xu J.; Lu Y.; Ding F.; Reversal of diabetes in mice by intrahepatic injection of bone-derived GFP-murine mesenchymal stem cells infected with the recombinant retrovirus-carrying human insulin gene. World J Surg 2007,31,1872-1882","journal-title":"World J Surg"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.biochi.2015.12.002","volume":"121","author":"Hegde V.","year":"2016","unstructured":"Hegde V.; Na H-N.; Dubuisson O.; An adenovirus-derived protein: a novel candidate for anti-diabetic drug development. Biochemie 2016,121,140-150","journal-title":"Biochemie"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","volume":"65","author":"D\u2019Avola D.","year":"2016","unstructured":"D\u2019Avola D.; L&#xF3;pez-Franco E.; Sangro B.; Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol 2016,65,776-783","journal-title":"J Hepatol"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"16363","DOI":"10.1073\/pnas.0904514106","volume":"106","author":"Brantly M.L.","year":"2009","unstructured":"Brantly M.L.; Chulay J.D.; Wang L.;  Proc Natl Acad Sci USA 2009,106,16363-16368","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1089\/hum.2011.053","volume":"22","author":"Flotte T.R.","year":"2011","unstructured":"Flotte T.R.; Trapnell B.C.; Humphries M.; Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1- antitrypsin: interim results. Hum Gene Ther 2011,22,1239-1247","journal-title":"Hum Gene Ther"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V95.3.820.003k32_820_828","volume":"95","author":"Balagu&#xE9; C.","year":"2000","unstructured":"Balagu&#xE9; C.; Zhou J.; Dai Y.; Sustained high-level expression of full-length human factor VIII and a restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000,95,820-828","journal-title":"Blood"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1073\/pnas.92.5.1401","volume":"92","author":"Dai Y.","year":"1995","unstructured":"Dai Y.; Schwarz E.M.; Gu D.; Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows long-term expression. Proc Natl Acad Sci USA 1995,92,1401-1405","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1073\/pnas.91.6.2353","volume":"91","author":"Kay M.A.","year":"1994","unstructured":"Kay M.A.; Landen C.N.; Rothenberg S.R.; In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994,91,2353-2357","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/hum.1995.6.8-1039","volume":"6","author":"Fang B.","year":"1995","unstructured":"Fang B.; Eisensmith R.C.; Wang H.; Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995,6,1039-1044","journal-title":"Hum Gene Ther"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","volume":"125","author":"Crudele J.M.","year":"2015","unstructured":"Crudele J.M.; Finn J.D.; Siner J.I.; AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 2015,125,1553-1561","journal-title":"Blood"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","volume":"29","author":"Doering C.B.","year":"2018","unstructured":"Doering C.B.; Denning G.; Shields J.E.; Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy of hemophilia A. Hum Gene Ther 2018,29,1183-1201","journal-title":"Hum Gene Ther"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2015-09-671420","volume":"127","author":"Marcos-Contreras O.A.","year":"2016","unstructured":"Marcos-Contreras O.A.; Smith S.M.; Bellinger D.A.; Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood 2016,127,565-571","journal-title":"Blood"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2016.87","volume":"24","author":"Garcia-Gomez M.","year":"2016","unstructured":"Garcia-Gomez M.; Calabria A.; Garcia-Bravo M.; Safe and efficient gene therapy for pyruvate kinase deficiency. Mol Ther 2016,24,1187-1198","journal-title":"Mol Ther"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/ATVBAHA.110.202796","volume":"30","author":"Huang N.F.","year":"2010","unstructured":"Huang N.F.; Niiyama H.; Peter C.; Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion. Arterioscler Thromb Vasc Biol 2010,30,984-991","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jvs.2011.03.278","volume":"54","author":"Saqib A.","year":"2011","unstructured":"Saqib A.; Prasad K-M.R.; Katwal A.B.; Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind limb ischemia in BALB\/c mice. J Vasc Surg 2011,54,810-818","journal-title":"J Vasc Surg"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40259-017-0255-0","volume":"32","author":"Chapin J.C.","year":"2018","unstructured":"Chapin J.C.; Monahan P.E.; Gene therapy for hemophilia. BioDrugs 2018,32,9-25","journal-title":"BioDrugs"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/blood.2019003777","volume":"138","author":"Leebeek F.W.","year":"2021","unstructured":"Leebeek F.W.; Miesbach W.; Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 2021,138,923-931","journal-title":"Blood"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/hae.13011","volume":"22","author":"Spencer H.T.","year":"2016","unstructured":"Spencer H.T.; Riley B.E.; Doering C.B.; State of the art: gene therapy of haemophilia. Haemophilia 2016,22(Suppl. 5),66-71","journal-title":"Haemophilia"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","volume":"2019","author":"Nathwani A.C.","year":"2019","unstructured":"Nathwani A.C.; Gene therapy for hemophilia. Hematology (Am Soc Hematol Educ Program) 2019,2019,1-8","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"Nathwani A.C.","year":"2014","unstructured":"Nathwani A.C.; Reiss U.M.; Tuddenham E.G.; Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014,371,1994-2004","journal-title":"N Engl J Med"},{"key":"ref=165","first-page":"99","author":"Kim J.","year":"2008","unstructured":"Kim J.; Yoon Y.S.; Lee H.; AAV-GAD gene for rat models of neuropathic pain and Parkinson\u2019s disease. Acta Neurochir 2008(Suppl. 101),99-105","journal-title":"Acta Neurochir"},{"key":"ref=166","first-page":"1276","volume":"114","author":"Fan D.","year":"2001","unstructured":"Fan D.; Shen Y.; Kang D.; Adeno-associated virus vector-mediated triple gene transfer of dopamine synthetic enzymes. Chin Med J 2001,114,1276-1279","journal-title":"Chin Med J"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(00)02915-2","volume":"886","author":"Bj&#xF6;rklund A.","year":"2000","unstructured":"Bj&#xF6;rklund A.; Kirik D.; Rosenblad C.; Towards a neuroprotective gene therapy for Parkinson\u2019s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000,886,82-98","journal-title":"Brain Res"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"Kordower J.H.","year":"2000","unstructured":"Kordower J.H.; Emborg M.E.; Bloch J.H.; Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate model of Parkinson\u2019s disease. Science 2000,290,767-773","journal-title":"Science"},{"key":"ref=169","first-page":"107\u201313","volume":"1061","year":"2005","unstructured":"AAV2\/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy. Brain Res 1 Wu K, Meyer EM, Bennett JA, et al2005,1061,107\u201313","journal-title":"Brain Res"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00401-015-1498-9","volume":"131","author":"Fol R.","year":"2016","unstructured":"Fol R.; Bradeau J.; Ludewig S.; Viral gene transfer of APPs&#x3B1; rescues synaptic failure in an Alzheimer\u2019s disease model. Acta Neuropathol 2016,131,247-266","journal-title":"Acta Neuropathol"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/cns.12312","volume":"20","author":"Revilla S.","year":"2014","unstructured":"Revilla S.; Ursulet S.; Alvarez-Lopez J.M.; Lenti-GDNF gene therapy protects against Alzheimer\u2019s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci Ther 2014,20,961-972","journal-title":"CNS Neurosci Ther"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neurobiolaging.2019.02.003","volume":"78","author":"Zeng C-Y.","year":"2019","unstructured":"Zeng C-Y.; Yang T-T.; Zhou H-J.; Lentiviral vector-mediated overexpression of klotho in the brain improves Alzheimer\u2019s disease-like pathology and cognitive deficits in mice. Neurobiol Aging 2019,78,18-28","journal-title":"Neurobiol Aging"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","volume":"29","author":"Rosenberg J.B.","year":"2018","unstructured":"Rosenberg J.B.; Kaplitt M.G.; De B.P.; AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease. Hum Gene Ther Clin Dev 2018,29,24-47","journal-title":"Hum Gene Ther Clin Dev"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","volume":"24","author":"Miniarikova J.","year":"2017","unstructured":"Miniarikova J.; Zimmer V.; Martier R.; AAV5-miHTT gene therapy demonstrates suppression of huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease. Gene Ther 2017,24,630-639","journal-title":"Gene Ther"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","volume":"26","author":"Evers M.M.","year":"2018","unstructured":"Evers M.M.; Miniarikova J.; Juhas S.; AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in Huntington\u2019s disease minipig model. Mol Ther 2018,26,2163-2177","journal-title":"Mol Ther"},{"key":"ref=176","first-page":"153","volume":"24","author":"Sinnett S.E.","year":"2017","unstructured":"Sinnett S.E.; Gray S.J.; Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome. Discov Med 2017,24,153-159","journal-title":"Discov Med"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1212\/01.wnl.0000312381.29287.ff","volume":"70","author":"Eberling J.L.","year":"2008","unstructured":"Eberling J.L.; Jagust W.J.; Christine C.W.; Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008,70,1980-1983","journal-title":"Neurology"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","volume":"383","author":"Palfi S.","year":"2014","unstructured":"Palfi S.; Gurruchaga J.M.; Scott Ralph G.; Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial. Lancet 2014,383,1138-1146","journal-title":"Lancet"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","volume":"75","author":"Rafii M.S.","year":"2018","unstructured":"Rafii M.S.; Tuszynski M.H.; Thomas R.G.; Adeno-associated viral vector (Serotype 2)\u2013nerve growth factor for patients with Alzheimer Disease. JAMA Neurol 2018,75,834-841","journal-title":"JAMA Neurol"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41434-019-0085-4","volume":"26","author":"Pattali R.","year":"2019","unstructured":"Pattali R.; Mou Y.; Li X-J.; AAV9 vector: a novel modality in gene therapy for spinal muscular atrophy. Gene Ther 2019,26,287-295","journal-title":"Gene Ther"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"Mendell J.R.","year":"2017","unstructured":"Mendell J.R.; Al-Zaidy S.; Schell R.; Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017,377,1713-1722","journal-title":"N Engl J Med"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"580179","DOI":"10.3389\/fnins.2020.580179","volume":"14","author":"Martier R.","year":"2020","unstructured":"Martier R.; Konstantinova P.; Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock. Front Neurosci 2020,14,580179","journal-title":"Front Neurosci"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1128\/JVI.80.4.1959-1964.2006","volume":"80","author":"Gao W.","year":"2006","unstructured":"Gao W.; Soloff A.C.; Lu X.; Protection of mice and poultry from lethal HSN1 avian influenza virus through adenovirus-based immunization. J Virol 2006,80,1959-1964","journal-title":"J Virol"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/viro.2000.0635","volume":"278","author":"Schultz-Cherry S.","year":"2000","unstructured":"Schultz-Cherry S.; Dybing J.K.; Davis N.L.; Influenza virus (a\/HK\/156\/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong origin H5N1 viruses. Virology 2000,278,55-59","journal-title":"Virology"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","volume":"183","author":"Fleeton M.N.","year":"2001","unstructured":"Fleeton M.N.; Chen M.; Berglund P.; Self-replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001,183,1395-1398","journal-title":"J Infect Dis"},{"key":"ref=186","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","volume":"36","author":"Chattopadhyay A.","year":"2018","unstructured":"Chattopadhyay A.; Aquila P.V.; Bopp N.E.; A recombinant virus vaccine that protects both against Chikungunya and Zika virus infections. Vaccine 2018,36,3894-3900","journal-title":"Vaccine"},{"key":"ref=187","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2008.033","volume":"19","author":"Lin J.","year":"2008","unstructured":"Lin J.; Calcedo R.; Vanderberghe L.H.; Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 gag vaccines. Hum Gene Ther 2008,19,663-669","journal-title":"Hum Gene Ther"},{"key":"ref=188","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1099\/0022-1317-80-1-217","volume":"80","author":"Rodr G.D.","year":"1999","unstructured":"Rodr G.D.; Rodr G.J.R.; Llorente M.; A human immunodeficiency virus type 1 Env-granulocyte-macrophage-colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine. J Gen Virol 1999,80,217-223","journal-title":"J Gen Virol"},{"key":"ref=189","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/JVI.75.9.4430-4434.2001","volume":"75","author":"McGettigan J.P.","year":"2001","unstructured":"McGettigan J.P.; Foley H.D.; Belyakov I.M.; Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J Virol 2001,75,4430-4434","journal-title":"J Virol"},{"key":"ref=190","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.imlet.2017.08.019","volume":"190","author":"Ajbani S.P.","year":"2017","unstructured":"Ajbani S.P.; Velhal S.M.; Kadam R.B.; Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and pol RT genes. Immunol Lett 2017,190,221-232","journal-title":"Immunol Lett"},{"key":"ref=191","doi-asserted-by":"crossref","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"Safronetz D.","year":"2015","unstructured":"Safronetz D.; Mire C.; Rosenke K.; A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl Trop Dis 2015,9,e0003736","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=192","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1016\/j.vaccine.2019.09.030","volume":"37","author":"Maruyama J.","year":"2019","unstructured":"Maruyama J.; Mateer E.J.; Manning J.T.; Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs. Vaccine 2019,37,6824-6831","journal-title":"Vaccine"},{"key":"ref=193","first-page":"32","volume":"6","author":"Fischer R.J.","year":"2020","unstructured":"Fischer R.J.; Purushotham J.N.; van Doremalen N.; ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. npj. Vaccines 2020,6,32","journal-title":"Vaccines"},{"key":"ref=194","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1128\/JVI.75.6.2660-2664.2001","volume":"75","author":"Wilson J.A.","year":"2001","unstructured":"Wilson J.A.; Hart M.K.; Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J Virol 2001,75,2660-2664","journal-title":"J Virol"},{"key":"ref=195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","volume":"349","author":"Marzi A.","year":"2015","unstructured":"Marzi A.; Robertson S.J.; Haddock E.; Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014\/2015 Ebola virus outbreak strain. Science 2015,349,739-742","journal-title":"Science"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"579297","DOI":"10.3389\/fgeed.2020.579297","volume":"2","author":"Lundstrom K.","year":"2020","unstructured":"Lundstrom K.; The Current Status of COVID-19 Vaccines. Front Genome Edit 2020,2,579297","journal-title":"Front Genome Edit"},{"key":"ref=197","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/v13020317","volume":"13","author":"Lundstrom K.","year":"2021","unstructured":"Lundstrom K.; Viral vectors for COVID-19 vaccine development. Viruses 2021,13,317","journal-title":"Viruses"},{"key":"ref=198","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1099\/vir.0.80844-0","volume":"86","author":"Faber M.","year":"2005","unstructured":"Faber M.; Lamirande E.W.; Roberts A.; A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005,86,1435-1440","journal-title":"J Gen Virol"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1371\/journal.pmed.0030525","volume":"3","author":"Deming D.","year":"2006","unstructured":"Deming D.; Sheahan T.; Heise M.; Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med 2006,3,e525","journal-title":"PLoS Med"},{"key":"ref=200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.aad1283","volume":"351","author":"Haagmans B.L.","year":"2016","unstructured":"Haagmans B.L.; van den Brand J.M.; Raj V.S.; An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 2016,351,77-81","journal-title":"Science"},{"key":"ref=201","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"van Doremalen N.","year":"2020","unstructured":"van Doremalen N.; Lambe T.; Spencer A.; ChAdOx1 nCov-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 2020,586,578-582","journal-title":"Nature"},{"key":"ref=202","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","volume":"11","author":"Wu S.","year":"2020","unstructured":"Wu S.; Zhong G.; Zhang J.; A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 2020,11,4081","journal-title":"Nat Commun"},{"key":"ref=203","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","volume":"11","author":"Feng L.","year":"2020","unstructured":"Feng L.; Wang Q.; Shan C.; An adenovirus-vectored COVID-19 vaccine confers protection from SARS-CoV-2 challenge in rhesus macaques. Nat Commun 2020,11,4207","journal-title":"Nat Commun"},{"key":"ref=204","first-page":"1128","volume":"20","author":"Balakrishnan V.V.S.","year":"2020","unstructured":"Balakrishnan V.V.S.; The arrival of Sputnik V. Lancet Comm 2020,20,1128","journal-title":"Lancet Comm"},{"key":"ref=205","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","volume":"26","author":"Tostanoski L.H.","year":"2020","unstructured":"Tostanoski L.H.; Wegmann F.; Martinot J.; Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med 2020,26,1694-1700","journal-title":"Nat Med"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","volume":"586","author":"Mercado N.B.","year":"2020","unstructured":"Mercado N.B.; Zahn R.; Wegmann F.; Loos C.; Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 2020,586,583-588","journal-title":"Nature"},{"key":"ref=207","doi-asserted-by":"crossref","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","volume":"12","author":"Erasmus J.H.","year":"2020","unstructured":"Erasmus J.H.; Khandhar A.P.; O\u2019Connor M.A.; An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med 2020,12,eabc9396","journal-title":"Sci Transl Med"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2019.03.008","volume":"215","author":"Purushotham J.","year":"2019","unstructured":"Purushotham J.; Lambe T.; Gilbert S.C.; Vaccine platforms for the prevention of Lassa fever. Immunol Lett 2019,215,1-11","journal-title":"Immunol Lett"},{"key":"ref=209","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","volume":"386","author":"Henao-Restrepo A.M.","year":"2015","unstructured":"Henao-Restrepo A.M.; Longini I.M.; Egger M.; Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015,386,857-866","journal-title":"Lancet"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","volume":"389","author":"Henao-Restrepo A.M.","year":"2017","unstructured":"Henao-Restrepo A.M.; Camacho A.; Longini I.M.; Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2017,389,505-518","journal-title":"Lancet"},{"key":"ref=211","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"Folegatti P.M.","year":"2020","unstructured":"Folegatti P.M.; Ewer K.J.; Aley P.K.; Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2 single-blind, randomised controlled trial. Lancet 2020,396,467-478","journal-title":"Lancet"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"Voysey M.","year":"2021","unstructured":"Voysey M.; Costa Clemens S.A.; Madhi S.A.; Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021,397,99-111","journal-title":"Lancet"},{"key":"ref=213","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"Zhu F.C.","year":"2020","unstructured":"Zhu F.C.; Guan X.H.; Li Y.H.; Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020,396,479-488","journal-title":"Lancet"},{"key":"ref=214","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"Wu S.","year":"2021","unstructured":"Wu S.; Huang J.; Zhang Z.; Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis 2021,21,1654-1664","journal-title":"Lancet Infect Dis"},{"key":"ref=215","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"Logunov D.Y.","year":"2020","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Zubkova O.V.; Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 2020,396,887-897","journal-title":"Lancet"},{"key":"ref=216","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"Logunov D.Y.","year":"2021","unstructured":"Logunov D.Y.; Dolzhikova I.V.; Shcheblyakov D.V.; Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19: an interim analysis of a randomised controlled phase 3 in Russia. Lancet 2021,397,671-681","journal-title":"Lancet"},{"key":"ref=217","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","volume":"384","author":"Sadoff J.","year":"2021","unstructured":"Sadoff J.; Le Gars M.; Shukarev G.; Interim results of a phase 1-2a trial of Ad26.COV.S Covid-19 vaccine. N Engl J Med 2021,384,1824-1835","journal-title":"N Engl J Med"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","volume":"325","author":"Stephenson K.E.","year":"2021","unstructured":"Stephenson K.E.; Le Gars M.; Sadoff J.; Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA 2021,325,1535-1544","journal-title":"JAMA"},{"key":"ref=219","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","volume":"584","author":"Callaway E.","year":"2020","unstructured":"Callaway E.; Russia\u2019s fast-track coronavirus vaccine draws outrage over safety. Nature 2020,584,334-335","journal-title":"Nature"},{"key":"ref=220","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1167\/iovs.02-1332","volume":"44","author":"Martin K.R.G.","year":"2003","unstructured":"Martin K.R.G.; Quigley H.A.; Zack D.J.; Gene therapy with brain-derived neurotrophic factor as a protection: retinal ganglion cells in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003,44,4357-4365","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=221","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddx028","volume":"26","author":"O\u2019Callaghan J.","year":"2017","unstructured":"O\u2019Callaghan J.; Crosbie D.E.; Cassidy P.S.; Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Hum Mol Genet 2017,26,1230-1246","journal-title":"Hum Mol Genet"},{"key":"ref=222","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hum.2015.142","volume":"27","author":"Bush R.A.","year":"2016","unstructured":"Bush R.A.; Zeng Y.; Colosi P.; Preclinical dose-escalation study of intravitreal AAV-RS1 gene therapy in a mouse model of X-linked retinoschisis: dose-dependent expression and improved retinal structure and function. Hum Gene Ther 2016,27,376-389","journal-title":"Hum Gene Ther"},{"key":"ref=223","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/hum.2019.017","volume":"30","author":"Feathers K.L.","year":"2019","unstructured":"Feathers K.L.; Jia L.; Dayanthi Perera N.; Development of a gene therapy vector for RDH12-associated retinal dystrophy. Hum Gene Ther 2019,30,1325-1335","journal-title":"Hum Gene Ther"},{"key":"ref=224","first-page":"543","volume":"90","author":"Hassall M.M.","year":"2017","unstructured":"Hassall M.M.; Barnard A.R.; MacLaren R.E.; Gene Therapy for Color Blindness. Yale J Biol Med 2017,90,543-551","journal-title":"Yale J Biol Med"},{"key":"ref=225","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nm1596","volume":"13","author":"Alexander J.J.","year":"2007","unstructured":"Alexander J.J.; Umino Y.; Everhart D.; Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007,13,685-687","journal-title":"Nat Med"},{"key":"ref=226","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/hmg\/ddq136","volume":"19","author":"Kom&#xE1;romy A.M.","year":"2010","unstructured":"Kom&#xE1;romy A.M.; Alexander J.J.; Rowlan J.S.; Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010,19,2581-2593","journal-title":"Hum Mol Genet"},{"key":"ref=227","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","volume":"390","author":"Heier J.S.","year":"2017","unstructured":"Heier J.S.; Kherani S.; Desai S.; Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase I, open-label trial. Lancet 2017,390,50-61","journal-title":"Lancet"},{"key":"ref=228","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","volume":"14","author":"Constable I.J.","year":"2016","unstructured":"Constable I.J.; Pierce C.M.; Lai C-M.; Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 2016,14,168-175","journal-title":"EBioMedicine"},{"key":"ref=229","doi-asserted-by":"crossref","first-page":"7108948","DOI":"10.1155\/2018\/7108948","volume":"2018","author":"Ratican S.E.","year":"2018","unstructured":"Ratican S.E.; Osborne A.; Martin K.R.; Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and Leber\u2019s hereditary optic neuropathy. Neural Plast 2018,2018,7108948","journal-title":"Neural Plast"},{"key":"ref=230","first-page":"2016","volume":"6","author":"Wan X.","year":"2016","unstructured":"Wan X.; Pei H.; Zhao M-J.; Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy. Sci Rep 2016,6,2016","journal-title":"Sci Rep"},{"key":"ref=231","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"Guy J.","year":"2017","unstructured":"Guy J.; Feuer W.J.; Davis J.L.; Gene therapy for Leder hereditary optic neuropathy: low and medium-dose visual results. Ophthalmology 2017,124,1621-1634","journal-title":"Ophthalmology"},{"key":"ref=232","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","volume":"125","author":"Vignal C.","year":"2018","unstructured":"Vignal C.; Uretsky S.; Fitoussi S.; Safety of rAAV2\/2-ND4 gene therapy. Ophthalmology 2018,125,945-947","journal-title":"Ophthalmology"},{"key":"ref=233","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"Russell S.","year":"2017","unstructured":"Russell S.; Bennett J.; Wellman J.A.; Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017,390,849-860","journal-title":"Lancet"},{"key":"ref=234","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","volume":"25","author":"Chamberlain J.R.","year":"2017","unstructured":"Chamberlain J.R.; Chamberlain J.S.; Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther 2017,25,1125-1131","journal-title":"Mol Ther"},{"key":"ref=235","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0014-5793(98)00251-8","volume":"425","author":"Yuasa K.","year":"1998","unstructured":"Yuasa K.; Miaygoe Y.; Yamamoto K.; Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 1998,425,329-336","journal-title":"FEBS Lett"},{"key":"ref=236","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/S0006-291X(02)00362-5","volume":"293","author":"Sakamoto M.","year":"2002","unstructured":"Sakamoto M.; Yuasa K.; Yoshimura M.; Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002,293,1265-1272","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=237","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nm1439","volume":"12","author":"Gregorevic P.","year":"2006","unstructured":"Gregorevic P.; Allen J.M.; Minami E.; rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006,12,787-789","journal-title":"Nat Med"},{"key":"ref=238","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2012.111","volume":"20","author":"Wang Z.","year":"2012","unstructured":"Wang Z.; Storb R.; Halbert C.L.; Successful regional delivery and long-term expression of 1958 a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther 2012,20,1501-1507","journal-title":"Mol Ther"},{"key":"ref=239","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1038\/ncomms14848","volume":"8","author":"Malerba A.","year":"2017","unstructured":"Malerba A.; Klein P.; Bachtarzi H.; PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 2017,8,14848","journal-title":"Nat Commun"},{"key":"ref=240","first-page":"35ra42","volume":"235","author":"Valori C.F.","year":"2010","unstructured":"Valori C.F.; Ning K.; Wyles M.; Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010,235,35ra42","journal-title":"Sci Transl Med"},{"key":"ref=241","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ana.24332","volume":"77","author":"Duque S.I.","year":"2015","unstructured":"Duque S.I.; Arnold W.D.; Odermatt P.; A large animal model of spinal muscular atrophy and correction of phenotype. Ann Neurol 2015,77,399-414","journal-title":"Ann Neurol"},{"key":"ref=242","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"Mendell J.R.","year":"2020","unstructured":"Mendell J.R.; Sahenk Z.; Lehman K.; (2020) Assessment of systemic delivery of rAAVrh74. MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy. JAMA Neurol 2020,77,1122-1131","journal-title":"JAMA Neurol"},{"key":"ref=243","doi-asserted-by":"crossref","first-page":"10613","DOI":"10.1073\/pnas.90.22.10613","volume":"90","author":"Flotte T.R.","year":"1993","unstructured":"Flotte T.R.; Afione S.A.; Conrad C.; Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993,90,10613-10617","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=244","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"O\u2019Sullivan B.P.","year":"2009","unstructured":"O\u2019Sullivan B.P.; Freedman S.D.; Cystic fibrosis. Lancet 2009,373(9678),1891-1904","journal-title":"Lancet"},{"key":"ref=245","first-page":"658","volume":"3","author":"Conrad C.K.","year":"1996","unstructured":"Conrad C.K.; Allen S.S.; Afione S.A.; Safety of single-dose administration of an adeno1348 associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996,3,658-668","journal-title":"Gene Ther"},{"key":"ref=246","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/hum.2017.201","volume":"29","author":"Cao H.","year":"2018","unstructured":"Cao H.; Ouyang H.; Grasemann H.; Transducing Airway Basal Cells with a Helper-Dependent Adenoviral Vector for Lung Gene Therapy. Hum Gene Ther 2018,29,643-652","journal-title":"Hum Gene Ther"},{"key":"ref=247","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3390\/genes10030218","volume":"10","author":"Marquez Loza L.I.","year":"2019","unstructured":"Marquez Loza L.I.; Yuen E.C.; McCray P.B.; Lentiviral vectors for the treatment and prevention of cystic fibrosis lung disease. Genes 2019,10,218","journal-title":"Genes"},{"key":"ref=248","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1089\/10430340260355365","volume":"13","author":"Limberis M.","year":"2002","unstructured":"Limberis M.; Anson D.S.; Fuller M.; Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002,13,1961-1970","journal-title":"Hum Gene Ther"},{"key":"ref=249","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/srep01287","volume":"3","author":"Farrow N.","year":"2013","unstructured":"Farrow N.; Miller D.; Cmielewski P.; Airway gene transfer in a non-human primate: lentiviral gene expression in marmoset lungs. Sci Rep 2013,3,1287","journal-title":"Sci Rep"},{"key":"ref=250","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/mt.2010.13","volume":"18","author":"Mitomo K.","year":"2010","unstructured":"Mitomo K.; Griesenbach U.; Inoue M.; Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010,18,1173-1182","journal-title":"Mol Ther"},{"key":"ref=251","doi-asserted-by":"crossref","first-page":"e88730","DOI":"10.1172\/jci.insight.88730","volume":"1","author":"Cooney A.L.","year":"2016","unstructured":"Cooney A.L.; Abou Alaiwa M.H.; Shah V.S.; Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. JCI Insight 2016,1,e88730","journal-title":"JCI Insight"},{"key":"ref=252","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/thoraxjnl-2016-208406","volume":"72","author":"Alton E.W.F.W.","year":"2017","unstructured":"Alton E.W.F.W.; Beekman J.M.; Boyd A.C.; Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax 2017,72,137-147","journal-title":"Thorax"},{"key":"ref=253","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.omtm.2018.03.002","volume":"9","author":"Poletti V.","year":"2018","unstructured":"Poletti V.; Charrier S.; Corre G.; Preclinical Development of a Lentiviral Vector for Gene Therapy of X-Linked Severe Combined Immunodeficiency. Mol Ther Methods Clin Dev 2018,9,257-269","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref=254","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood.V128.22.4705.4705","volume":"128","author":"Poletti V.","year":"2016","unstructured":"Poletti V.; Charrier S.; Martin S.; Preclinical Development of Gene Therapy for X-linked Severe Combined Immunodeficiency (SCID-X1). Blood 2016,128,4705","journal-title":"Blood"},{"key":"ref=255","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"Cavazzana-Calvo M.","year":"2000","unstructured":"Cavazzana-Calvo M.; Hacein-Bey S.; de Saint B.G.; Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000,288,669-672","journal-title":"Science"},{"key":"ref=256","doi-asserted-by":"crossref","first-page":"e20190607","DOI":"10.1084\/jem.20190607","volume":"217","author":"Fischer A.","year":"2020","unstructured":"Fischer A.; Hacein-Bey-Abina S.; Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med 2020,217,e20190607","journal-title":"J Exp Med"},{"key":"ref=257","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","volume":"364","author":"Gaspar H.B.","year":"2004","unstructured":"Gaspar H.B.; Parsley K.L.; Howe S.; Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004,364,2181-2187","journal-title":"Lancet"},{"key":"ref=258","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","volume":"118","author":"Howe S.J.","year":"2008","unstructured":"Howe S.J.; Mansour M.R.; Schwarzwaelder K.; Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008,118,3143-3150","journal-title":"J Clin Invest"},{"key":"ref=259","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2022016196","volume":"140","author":"Cuvelier G.D.E.","year":"2022","unstructured":"Cuvelier G.D.E.; Logan B.R.; Prockop S.E.; Outcomes following treatment of ADA-deficient severe combined immune deficiency: a report from the PIDTC. Blood 2022,140,685-705","journal-title":"Blood"},{"key":"ref=260","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","volume":"384","author":"Kohn D.B.","year":"2021","unstructured":"Kohn D.B.; Booth C.; Shaw K.L.; Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med 2021,384,2002-2013","journal-title":"N Engl J Med"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523222666220921112753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/209017\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1566523222666220921112753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T08:46:25Z","timestamp":1679301985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/209017\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":260,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523222666220921112753","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}